Common week one experiences include mild appetite reduction that comes and goes, slight changes in how food tastes or appeals, occasional mild nausea, particularly after larger meals, and a subtle sense of fullness that arrives earlier during meals than usual
Contact the manufacturer's patient support Novo Nordisk for semaglutide, Eli Lilly for tirzepatide
The injection delivers the medication directly into the body's tissues, bypassing the digestive system
"I've always gone up and down, yo-yo, every diet," he said
June 26th, 2024: Study reveals GLP-1 drugs may cause bone density loss without exercise A recent study from the University of Copenhagen raises new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, highlighting potential bone density loss
The most common are 2 mg, 3 mg, 5 mg, and 10 mg